638 related articles for article (PubMed ID: 27426412)
1. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine: what's all the fuss about?
Barker R
Scand J Clin Lab Invest Suppl; 2016; 245():S2-5. PubMed ID: 27542001
[TBL] [Abstract][Full Text] [Related]
3. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
4. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
[TBL] [Abstract][Full Text] [Related]
5. The value proposition of molecular medicine.
Waldman SA; Terzic A
Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
7. Balancing the Economics and Ethics of Personalised Oncology.
Flaum N; Hall P; McCabe C
Trends Cancer; 2018 Sep; 4(9):608-615. PubMed ID: 30149879
[TBL] [Abstract][Full Text] [Related]
8. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
Doble B; Tan M; Harris A; Lorgelly P
Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
10. The Health Technology Assessment of companion diagnostics: experience of NICE.
Byron SK; Crabb N; George E; Marlow M; Newland A
Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
12. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.
Miller AM; Omenn GS; Kean MA
Clin Cancer Res; 2016 May; 22(10):2335-41. PubMed ID: 27087022
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
15. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
17. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
[TBL] [Abstract][Full Text] [Related]
18. Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice.
Madhavan S; Subramaniam S; Brown TD; Chen JL
Am Soc Clin Oncol Educ Book; 2018 May; 38():546-553. PubMed ID: 30231369
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
[TBL] [Abstract][Full Text] [Related]
20. [Molecular-Genetic Diagnosis and Molecular-Targeted Therapy in Cancer: Challenges in the Era of Precision Medicine].
Miyachi H
Rinsho Byori; 2015 Oct; 63(10):1188-93. PubMed ID: 26897855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]